New driver mutations in non-small-cell lung cancer
Top Cited Papers
- 1 February 2011
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 12 (2), 175-180
- https://doi.org/10.1016/s1470-2045(10)70087-5
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences of the United States of America, 2008
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences of the United States of America, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- Raf kinases: Function, regulation and role in human cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002